– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ...
SAN DIEGO and TOKYO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced the Journal of Clinical Oncology ...
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...
Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1-2N0M0) Oral Tongue Squamous Cell Carcinoma Adults with FLT3-ITD AML in first remission underwent HCT and were randomly ...
6don MSN
Breast cancer drug boosts leukemia treatment: Unexpected duo shows promise in overcoming resistance
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...
Kura Oncology (KURA) is in good shape with respect to its pipeline in terms of the development of its lead drug, ziftomenib, for the treatment of patients with relapsed/refractory NPM1-mutated Acute ...
Syndax Pharmaceuticals is now a commercial-stage biopharma with two FDA-approved drugs: Revuforj and Niktimvo. Syndax's Revuforj leads in efficacy for AML, with rapid market penetration and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback